Triple III comparison of leflunomide alone versus two DMARD combinations (leflunomide-hydroxychloroquine-sulfasalazine or methotrexate-hydroxychloroquine-sulfasalazine) in the treatment of rheumatoid arthritis

Trial Profile

Triple III comparison of leflunomide alone versus two DMARD combinations (leflunomide-hydroxychloroquine-sulfasalazine or methotrexate-hydroxychloroquine-sulfasalazine) in the treatment of rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Leflunomide (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jun 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top